Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction
- PMID: 40588539
- DOI: 10.1038/s42255-025-01314-w
Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction
Abstract
Tauopathies encompass a range of neurodegenerative disorders, such as Alzheimer's disease (AD) and frontotemporal lobar degeneration with tau inclusions (FTLD-tau), for which there are currently no successful treatments. Here, we show impaired glycogen metabolism in the brain of a tauopathy Drosophila melanogaster model and people with AD, indicating a link between tauopathies and glycogen metabolism. We demonstrate that the breakdown of neuronal glycogen ameliorates the tauopathy phenotypes in flies and induced pluripotent stem cell (iPSC)-derived neurons from people with FTLD-tau. Glycogen breakdown redirects glucose flux to the pentose phosphate pathway and alleviates oxidative stress. Our findings uncover a critical role for the neuroprotective effects of dietary restriction (DR) by increasing glycogen breakdown. Mechanistically, we show a potential interaction between tau protein and glycogen, suggesting a vicious cycle in which tau binding promotes glycogen accumulation in neurons, which in turn exacerbates tau accumulation which further disrupts cellular homeostasis. Our studies identify impaired glycogen metabolism as a key hallmark for tauopathies and offer a promising therapeutic target in tauopathy and other neurodegenerative diseases.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: P.K. is a founder and a member of the scientific advisory board at Juvify Bio. The other authors have no competing interests.
Update of
-
Neuronal Glycogen Breakdown Mitigates Tauopathy via Pentose Phosphate Pathway-Mediated Oxidative Stress Reduction.Res Sq [Preprint]. 2023 Nov 8:rs.3.rs-3526342. doi: 10.21203/rs.3.rs-3526342/v1. Res Sq. 2023. Update in: Nat Metab. 2025 Jul;7(7):1375-1391. doi: 10.1038/s42255-025-01314-w. PMID: 37986935 Free PMC article. Updated. Preprint.
References
MeSH terms
Substances
Grants and funding
- R01 AG045835/AG/NIA NIH HHS/United States
- R01AG045835/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01AG070193/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01AG038688/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 2019-A-026-FEL/Larry L. Hillblom Foundation (Larry L. Hillblom Foundation, Inc.)
- T32AG000266-23/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01 AG038688/AG/NIA NIH HHS/United States
- P01AG066591/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R21AG054121/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 1S10 OD016281/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R21 AG054121/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases